Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging

Synapse

Volumn 40, Issue 1, 2001, Pages 19-26

  Ruottinen, Hanna M ^a   Niinivirta, Mikko ^a   Bergman, Jörgen ^b   Oikonen, Vesa ^b   Solin, Olof ^b   Eskola, Olli ^b   Eronen, Esa ^b   Sonninen, Pirkko ^a   Rinne, Urpo K ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU PET CENTRE   (Finland)

Author keywords

COMT inhibition; Dopamine storage; Entacapone; Fluorodopa positron emission tomography; Parkinson's disease with end of dose fluctuations

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE; ENTACAPONE; LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORPUS STRIATUM; DIAGNOSTIC IMAGING; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; OCCIPITAL CORTEX; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PUTAMEN;

AGED; ANTIPARKINSON AGENTS; BRAIN; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; DIHYDROXYPHENYLALANINE; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOVEMENT; PARKINSON DISEASE; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035118665     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2396(200104)40:1<19::AID-SYN1022>3.0.CO;2-7     Document Type: Article

References (23)

1. 18F]-fluoride
2. Synthesis of some novel potent and selective catechol-O-methyltransferase inhibitors
3. Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-dopa trapping in MPTP-induced parkinsonism in monkeys
4. Le test á la L-Dopa dans la maladie de Parkinson
5. Unified Parkinson's Disease Rating Scale
6. Graphical analysis of 6-fluoro-L-dopa trapping: Effect of inhibition of catechol-O-methyltransferase
7. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: Effect of the plasma 3-O-methyldopa fraction on data analysis
8. Entacapone in combination with standard or controlled-release levodopa/carbidopa: A clinical and pharmaco-kinetic study in patients with Parkinson's disease
9. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers
10. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography
11. Investigation of the performance of the General Electric ADVANCE positron emission tomograph in 3D mode
12. 18F]fluoro-DOPA metabolism in monkeys and humans: Biochemical parameters for the formulation of tracer kinetic models with positron emission tomography
13. Effects of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and cardiovascular responses in patients with Parkinson's disease
14. 18F]fluoro-L-dopa
15. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients
16. Accurate three-dimensional registration of CT, PET, and/or MR images of the brain
17. 18F]fluoro-L-DOPA uptake in rhesus monkey: Pharmacological influence of aromatic amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) inhibition
18. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations
19. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease
20. 18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease
21. 18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: Differing response in relation to presynaptic dopaminergic dysfunction
22. 18F]Fluoro-L-dopa metabolites: Importance in interpretation of PET results
23. 18F]-6-fluorodopa metabolism: Implications for levodopa therapy of Parkinson's disease